Table 2 Patient and tumor baseline characteristics and locations of nodal relapses
From: PET/CT of breast cancer regional nodal recurrences: an evaluation of contouring atlases
|  |  | All patients N = 69 | RNI N = 30 | Tangent only N = 16 | No RT N = 23 | P-value |
|---|---|---|---|---|---|---|
Age Median (Range) |  | 49 (29–84) | 48.5 (30–76) | 52 (35–75) | 48 (29–84) | 0.45 |
Laterality | Right | 34 (49%) | 14 (47%) | 8 (50%) | 12 (52%) | 0.92 |
Left | 35 (51%) | 16 (53%) | 8 (50%) | 11 (48%) | ||
Grade | 1 | 6 (9%) | 1 (3%) | 1 (6%) | 4 (17%) | 0.27 |
2 | 27 (39%) | 11 (37%) | 8 (50%) | 8 (35%) | ||
3 | 32 (46%) | 17 (57%) | 6 (38%) | 9 (40%) | ||
Unknown | 4 (4%) | 1 (3%) | 1 ((6%) | 2 (9%) | ||
Tumor size | 0-2 cm | 32 (46%) | 10 (33%) | 11 (69%) | 11 (48%) | 0.03 |
> 2–5 cm | 26 (38%) | 12 (40%) | 5 (31%) | 9 (40%) | ||
>  5 cm | 9 (14%) | 8 (27%) | 0 (0%) | 1 (4%) | ||
Unknown | 2 (3%) | 0 (0%) | 0 (0%) | 2 (9%) | ||
Number of positive nodes | 0 | 32 (46%) | 5 (17%) | 14 (88%) | 13 (57%) | < 0.01 |
1–3 | 19 (28%) | 13 (43%) | 2 (12%) | 4 (17%) | ||
≥ 4 | 14 (20%) | 11 (37%) | 0 (0%) | 3 (13%) | ||
Unknown | 4 (6%) | 1 (3%) | 0 (0%) | 3 (13%) | ||
Stage | I | 24 (35%) | 6 (20%) | 6 (38%) | 12 (52%) | < 0.01 |
II | 28(40%) | 16 (54%) | 6 (38%) | 6 (26%) | ||
III | 6(9%) | 4 (13%) | 0 (0%) | 2 (9%) | ||
Unknown | 11(16%) | 4 (13%) | 4 (24%) | 3 (13%) | ||
Her2 status | Positive | 6 (9%) | 4 (13%) | 1 (6%) | 1 (4%) | 0.54 |
Negative | 40 (58%) | 19(63%) | 9 (56%) | 12 (52%) | ||
Unknown | 23 (33%) | 7 (23%) | 6 (38%) | 10 (44%) | ||
Estrogen status | Positive | 47 (68%) | 17 (57%) | 12 (75%) | 18 (78%) | 0.11 |
Negative | 20 (29%) | 13 (43%) | 3 (19%) | 4 (17%) | ||
Unknown | 2 (3%) | 0 (0%) | 1 (6%) | 1 (4%) | ||
Surgery | BCS | 31 (45%) | 10 (33%) | 13 (81%) | 8 (35%) | < 0.01 |
Mastectomy | 38 (55%) | 20 (66%) | 3 (19%) | 15 (65%) | ||
Axillary lymph node dissection | Yes | 53 (77%) | 27 (90%) | 12 (75%) | 14 (61%) | 0.04 |
No | 16 (23%) | 3 (10%) | 4 (25%) | 9 (31%) | ||
Chemotherapy | Yes | 46 (67%) | 23 (77%) | 12 (75%) | 11 (48%) | 0.07 |
No | 23 (33%) | 7 (23%) | 4 (25%) | 12 (52%) | ||
Hormone therapy | Yes | 41 (59%) | 16 (53%) | 12 (75%) | 13 (57%) | 0.14 |
No | 28(41%) | 14 (47%) | 4 (25%) | 10 (43%) | ||
Isolated RNR RNR and distant metastases | Â | 31 (45%) | 9 (30%) | 9 (56%) | 13 (57%) | 0.09 |
| Â | 38 (55%) | 21 (70%) | 7 (44%) | 10 (43%) | ||
Number of RNR | Â | 226 | 92 | 48 | 86 | Â |
RNR per Patient | Â | 3.3 | 3.1 | 3.0 | 3.7 | 0.28 |
RNR Locations | SCF (CTV4) | 35 | 20 | 7 | 8 | Â |
(ESTRO CTV) | Axilla Level 1 (CTV1) | 64 | 22 | 15 | 27 | Â |
| Â | Axilla Level 2 (CTV2) | 27 | 7 | 8 | 12 | Â |
| Â | Interpectoral | 11 | 5 | 1 | 5 | Â |
| Â | Axilla Level 3 (CTV3) | 34 | 12 | 6 | 16 | Â |
| Â | IMN | 34 | 18 | 7 | 9 | Â |
| Â | RADCOMP Posterior Neck | 21 | 8 | 4 | 9 | Â |